A clinical and molecular review of inverted papilloma of the urinary tract: how to handle?
Corresponding Author
Peter Hjorth Jørgensen
Department of Urology, Bispebjerg and Frederiksberg Hospitals, University of Copenhagen, Copenhagen, Denmark
Peter Hjorth Jørgensen, Nordre Fasanvej 57, 2000 Frederiksberg C, Denmark. e-mail: [email protected]Search for more papers by this authorBen Vainer
Department of Pathology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
Search for more papers by this authorGregers Gautier Hermann
Department of Urology, Bispebjerg and Frederiksberg Hospitals, University of Copenhagen, Copenhagen, Denmark
Search for more papers by this authorCorresponding Author
Peter Hjorth Jørgensen
Department of Urology, Bispebjerg and Frederiksberg Hospitals, University of Copenhagen, Copenhagen, Denmark
Peter Hjorth Jørgensen, Nordre Fasanvej 57, 2000 Frederiksberg C, Denmark. e-mail: [email protected]Search for more papers by this authorBen Vainer
Department of Pathology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
Search for more papers by this authorGregers Gautier Hermann
Department of Urology, Bispebjerg and Frederiksberg Hospitals, University of Copenhagen, Copenhagen, Denmark
Search for more papers by this authorAbstract
Inverted papilloma (IP) of the urinary tract is classified by the World Health Organisation as a non-invasive urothelial tumour with normal to minimal cytological atypia of the neoplastic cells. During the 1980s, it came under suspicion of having a premalignant or malignant potential and of being concurrent with urothelial cell carcinoma (UCC). This quandary has been proven difficult to solve, due to the fact that IP is very rare and literature mostly consists of case reports with varying levels of information, making strong meta-analyses problematic. New immunohistochemical techniques and genetic approaches are more frequently being used in the attempt to achieve better classifications, prognosis and treatment of lesions hereunder IP. This review will, in our awareness, be the first to combine the knowledge from retrospective studies with these new approaches for determining a possible premalignant potential and concurrency with UCC and subsequently outline a recommendation for follow-up.
References
- 1Picozzi S, Casellato S, Bozzini G, Ratti D, Macchi A, Rubino B, et al. Inverted papilloma of the bladder: a review and an analysis of the recent literature of 365 patients. Urol Oncol 2013; 31: 1584–90.
- 2Bagley DH, McCue P, Blackstone AS. Inverted papilloma of renal pelvis: flexible ureteroscopic diagnosis and treatment. Urology 1990; 36: 336–8.
- 3Henderson DW, Allen PW, Bourne AJ. Inverted urinary papilloma: report of five cases and review of the literature. Virchows Arch A Pathol Anat Histol 1975; 366: 177–86.
- 4Paschkis R. Über adenoma der harnblase. Z. Urol Chir 1927; 21: 315–25.
- 5Potts IF, Hirst E. Inverted papilloma of the bladder. J Urol 1963; 90: 175–9.
- 6Kimura G, Tsuboi N, Nakajima H, Yoshida K, Masugi Y, Akimoto M. Inverted papilloma of the ureter with malignant transformation: a case report and review of the literature. The importance of the recognition of the inverted papillary tumor of the ureter. Urol Int 1987; 42: 30–6.
- 7Eble JN, Sauter G, Epstein JI, Sesterhenn IA (Eds.): World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. IARC Press: Lyon 2004.
- 8Kunze E, Schauer A, Schmitt M. Histology and histogenesis of two different types of inverted urothelial papillomas. Cancer 1983; 51: 348–58.
10.1002/1097-0142(19830115)51:2<348::AID-CNCR2820510231>3.0.CO;2-O CAS PubMed Web of Science® Google Scholar
- 9Hodges KB, Lopez-Beltran A, Maclennan GT, Montironi R, Cheng L. Urothelial lesions with inverted growth patterns: histogenesis, molecular genetic findings, differential diagnosis and clinical management. BJU Int 2011; 107: 532–7.
- 10Albores-Saavedra J, Chable-Montero F, Hernandez-Rodriguez OX, de Montante-Montes OD, Angeles-Angeles A. Inverted urothelial papilloma of the urinary bladder with focal papillary pattern: a previously undescribed feature. Ann Diagn Pathol 2009; 13: 158–61.
- 11Eiber M, van Oers JM, Zwarthoff EC, van der Kwast TH, Ulrich O, Helpap B, et al. Low frequency of molecular changes and tumor recurrence in inverted papillomas of the urinary tract. Am J Surg Pathol 2007; 31: 938–46.
- 12Amin MB, Gomez JA, Young RH. Urothelial transitional cell carcinoma with endophytic growth patterns: a discussion of patterns of invasion and problems associated with assessment of invasion in 18 cases. Am J Surg Pathol 1997; 21: 1057–68.
- 13Broussard JN, Tan PH, Epstein JI. Atypia in inverted urothelial papillomas: pathology and prognostic significance. Hum Pathol 2004; 35: 1499–504.
- 14Yafi FA, Brimo F, Steinberg J, Aprikian AG, Tanguay S, Kassouf W. Prospective analysis of sensitivity and specificity of urinary cytology and other urinary biomarkers for bladder cancer. Urol Oncol 2015; 33: 25–31.
- 15Highman WJ. Urinary cytology in inverted papilloma of the lower urinary tract. Acta Cytol 1978; 22: 335–8.
- 16Witjes JA, van Balken MR, van de Kaa CA. The prognostic value of a primary inverted papilloma of the urinary tract. J Urol 1997; 158: 1500–5.
- 17Patel P, Reikie BA, Maxwell JP, Yilmaz A, Gotto GT, Trpkov K. Long-term clinical outcome of inverted urothelial papilloma including cases with focal papillary pattern: is continuous surveillance necessary? Urology 2013; 82: 857–60.
- 18Sung MT, Maclennan GT, Lopez-Beltran A, Montironi R, Cheng L. Natural history of urothelial inverted papilloma. Cancer 2006; 107: 2622–7.
- 19Urakami S, Igawa M, Shirakawa H, Shiina H, Ishibe T. Biological characteristics of inverted papilloma of the urinary bladder. Br J Urol 1996; 77: 55–60.
- 20Wu TT, Wang JS, Huang JK, Lee YH, Jiaan BP, Chen WC. Inverted papilloma of the urinary bladder. Zhonghua Yi Xue Za Zhi (Taipei) 1996; 57: 59–63.
- 21Lee SH, Mah SY, Chung BH. Incidentally discovered inverted papilloma of the urinary bladder in patients with lower urinary tract symptoms. J Endourol 2010; 24: 271–5.
- 22Kilciler M, Bedir S, Erdemir F, Ors O, Kibar Y, Dayanc M. Evaluation of urinary inverted papillomas: a report of 13 cases and literature review. Kaohsiung J Med Sci 2008; 24: 25–30.
- 23Fine SW, Epstein JI. Inverted urothelial papillomas with foamy or vacuolated cytoplasm. Hum Pathol 2006; 37: 1577–82.
- 24Fine SW, Chan TY, Epstein JI. Inverted papillomas of the prostatic urethra. Am J Surg Pathol 2006; 30: 975–9.
- 25Ho H, Chen YD, Tan PH, Wang M, Lau WK, Cheng C. Inverted papilloma of urinary bladder: is long-term cystoscopic surveillance needed? A single center's experience Urology 2006; 68: 333–6.
- 26Terada T. Inverted variant of urothelial carcinoma of the urinary bladder: a report of three cases and a proposal for a new clinicopathologic entity. Int J Clin Exp Pathol 2013; 6: 766–70.
- 27Tiwari P, Tripathi A, Vijay M, Mitra B, Kumar S, Pal DK, et al. Inverted papilloma of the urinary bladder: rigorous surveillance needed? An Indian experience Indian J Cancer 2010; 47: 418–23.
- 28Cheon J, Kim HK, Kim JJ, Yoon DK, Koh SK, Kim IS. Malignant inverted papilloma of the urinary bladder: the histopathological aspect of malignant potential of inverted papilloma. J Korean Med Sci 1995; 10: 103–10.
- 29Asano K, Miki J, Maeda S, Naruoka T, Takahashi H, Oishi Y. Clinical studies on inverted papilloma of the urinary tract: report of 48 cases and review of the literature. J Urol 2003; 170: 1209–12.
- 30Yagi H, Igawa M, Shiina H, Shigeno K, Yoneda T, Wada Y, et al. Inverted papilloma of the urinary bladder in a girl. Urol Int 1999; 63: 258–60.
- 31Isaac J, Lowichik A, Cartwright P, Rohr R. Inverted papilloma of the urinary bladder in children: case report and review of prognostic significance and biological potential behavior. J Pediatr Surg 2000; 35: 1514–6.
- 32Brown AL, Cohen RJ. Inverted papilloma of the urinary tract. BJU Int 2011; 107(Suppl 3): 24–6.
- 33Cosgrove DJ, Monga M. Inverted papilloma as a cause of high-grade ureteral obstruction. Urology 2000; 56: 856.
- 34Monge Mirallas JM, Asensio LA, Martinez BF, Acinas GO. Report of 2 new cases of bladder inverted papilloma, one with them complicated with acute urinary obstruction. Actas Urol Esp 2000; 24: 419–22.
- 35Cheng CW, Chan LW, Chan CK, Ng CF, Cheung HY, Chan SY, et al. Is surveillance necessary for inverted papilloma in the urinary bladder and urethra? ANZ J Surg 2005; 75: 213–7.
- 36Caro DJ, Tessler A. Inverted papilloma of the bladder: a distinct urological lesion. Cancer 1978; 42: 708–13.
10.1002/1097-0142(197808)42:2<708::AID-CNCR2820420242>3.0.CO;2-7 CAS PubMed Web of Science® Google Scholar
- 37Holmang S, Andius P, Hedelin H, Wester K, Busch C, Johansson SL. Stage progression in Ta papillary urothelial tumors: relationship to grade, immunohistochemical expression of tumor markers, mitotic frequency and DNA ploidy. J Urol 2001; 165: 1124–8.
- 38Cummings R. Inverted papilloma of the bladder. J Pathol 1974; 112: 225–7.
- 39Matz LR, Wishart VA, Goodman MA. Inverted urothelial papilloma. Pathology 1974; 6: 37–44.
- 40Barghi MR, Hajimohammadmehdiarbab A, Moghaddam SM, Kazemi B. Correlation between human papillomavirus infection and bladder transitional cell carcinoma. BMC Infect Dis 2005; 5: 102.
- 41Moonen PM, Bakkers JM, Kiemeney LA, Schalken JA, Melchers WJ, Witjes JA. Human papilloma virus DNA and p53 mutation analysis on bladder washes in relation to clinical outcome of bladder cancer. Eur Urol 2007; 52: 464–8.
- 42Chan KW, Wong KY, Srivastava G. Prevalence of six types of human papillomavirus in inverted papilloma and papillary transitional cell carcinoma of the bladder: an evaluation by polymerase chain reaction. J Clin Pathol 1997; 50: 1018–21.
- 43Shigehara K, Sasagawa T, Doorbar J, Kawaguchi S, Kobori Y, Nakashima T, et al. Etiological role of human papillomavirus infection for inverted papilloma of the bladder. J Med Virol 2011; 83: 277–85.
- 44Gould VE, Schmitt M, Vinokurova S, Reddy VB, Bitterman P, Alonso A, et al. Human papillomavirus and p16 expression in inverted papillomas of the urinary bladder. Cancer Lett 2010; 292: 171–5.
- 45Alexander RE, Davidson DD, Lopez-Beltran A, Montironi R, Maclennan GT, Comperat E, et al. Human papillomavirus is not an etiologic agent of urothelial inverted papillomas. Am J Surg Pathol 2013; 37: 1223–8.
- 46McDaniel AS, Zhai Y, Cho KR, Dhanasekaran SM, Montgomery JS, Palapattu G, et al. HRAS mutations are frequent in inverted urothelial neoplasms. Hum Pathol 2014; 45: 1957–1965.
- 47Brennan P, Bogillot O, Cordier S, Greiser E, Schill W, Vineis P, et al. Cigarette smoking and bladder cancer in men: a pooled analysis of 11 case-control studies. Int J Cancer 2000; 86: 289–94.
10.1002/(SICI)1097-0215(20000415)86:2<289::AID-IJC21>3.0.CO;2-M CAS PubMed Web of Science® Google Scholar
- 48Brennan P, Bogillot O, Greiser E, Chang-Claude J, Wahrendorf J, Cordier S, et al. The contribution of cigarette smoking to bladder cancer in women (pooled European data). Cancer Causes Control 2001; 12: 411–7.
- 49Czerniak B, Chaturvedi V, Li L, Hodges S, Johnston D, Roy JY, et al. Superimposed histologic and genetic mapping of chromosome 9 in progression of human urinary bladder neoplasia: implications for a genetic model of multistep urothelial carcinogenesis and early detection of urinary bladder cancer. Oncogene 1999; 18: 1185–96.
- 50Sung MT, Eble JN, Wang M, Tan PH, Lopez-Beltran A, Cheng L. Inverted papilloma of the urinary bladder: a molecular genetic appraisal. Mod Pathol 2006; 19: 1289–94.
- 51Cheng L, Maclennan GT, Zhang S, Wang M, Pan CX, Koch MO. Laser capture microdissection analysis reveals frequent allelic losses in papillary urothelial neoplasm of low malignant potential of the urinary bladder. Cancer 2004; 101: 183–8.
- 52Uchida A, Tachibana M, Miyakawa A, Nakamura K, Murai M. Microsatellite analysis in multiple chromosomal regions as a prognostic indicator of primary bladder cancer. Urol Res 2000; 28: 297–303.
- 53Louhelainen J, Wijkstrom H, Hemminki K. Multiple regions with allelic loss at chromosome 3 in superficial multifocal bladder tumors. Int J Oncol 2001; 18: 203–10.
- 54Junker K, Boerner D, Schulze W, Utting M, Schubert J, Werner W. Analysis of genetic alterations in normal bladder urothelium. Urology 2003; 62: 1134–8.
- 55Johnson DE, Williams LT. Structural and functional diversity in the FGF receptor multigene family. Adv Cancer Res 1993; 60: 1–41.
- 56van Oers JM, Lurkin I, van Exsel AJ, Nijsen Y, van Rhijn BW, van der Aa MN, et al. A simple and fast method for the simultaneous detection of nine fibroblast growth factor receptor 3 mutations in bladder cancer and voided urine. Clin Cancer Res 2005; 11: 7743–8.
- 57van Rhijn BW, Lurkin I, Radvanyi F, Kirkels WJ, van der Kwast TH, Zwarthoff EC. The fibroblast growth factor receptor 3 (FGFR3) mutation is a strong indicator of superficial bladder cancer with low recurrence rate. Cancer Res 2001; 61: 1265–8.
- 58van Rhijn BW, Montironi R, Zwarthoff EC, Jobsis AC, van der Kwast TH. Frequent FGFR3 mutations in urothelial papilloma. J Pathol 2002; 198: 245–51.
- 59Lott S, Wang M, Zhang S, Maclennan GT, Lopez-Beltran A, Montironi R, et al. FGFR3 and TP53 mutation analysis in inverted urothelial papilloma: incidence and etiological considerations. Mod Pathol 2009; 22: 627–32.
- 60Weinstein JN, Akbani R, Broom BM, Wang W, Verhaak RG, McConkey D, et al. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 2014; 507: 315–22.
- 61Chan KW, Lam KY, Srivastava G. Accumulation of p53 protein in inverted transitional cell papilloma of the urinary bladder. Clin Mol Pathol 1996; 49: M43–5.
- 62Ouerhani S, Elgaaied AB. The mutational spectrum of HRAS, KRAS, NRAS and FGFR3 genes in bladder cancer. Cancer Biomark 2011; 10: 259–66.
- 63Cheng L, Davison DD, Adams J, Lopez-Beltran A, Wang L, Montironi R, et al. Biomarkers in bladder cancer: translational and clinical implications. Crit Rev Oncol Hematol 2014; 89: 73–111.
- 64Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Physiol 2000; 182: 311–22.
10.1002/(SICI)1097-4652(200003)182:3<311::AID-JCP1>3.0.CO;2-9 CAS PubMed Web of Science® Google Scholar
- 65Cheville JC, Wu K, Sebo TJ, Cheng L, Riehle D, Lohse CM, et al. Inverted urothelial papilloma: is ploidy, MIB-1 proliferative activity, or p53 protein accumulation predictive of urothelial carcinoma? Cancer 2000; 88: 632–6.
10.1002/(SICI)1097-0142(20000201)88:3<632::AID-CNCR21>3.0.CO;2-F CAS PubMed Web of Science® Google Scholar
- 66Jones TD, Zhang S, Lopez-Beltran A, Eble JN, Sung MT, Maclennan GT, et al. Urothelial carcinoma with an inverted growth pattern can be distinguished from inverted papilloma by fluorescence in situ hybridization, immunohistochemistry, and morphologic analysis. Am J Surg Pathol 2007; 31: 1861–7.
- 67Meeker AK, Hicks JL, Iacobuzio-Donahue CA, Montgomery EA, Westra WH, Chan TY, et al. Telomere length abnormalities occur early in the initiation of epithelial carcinogenesis. Clin Cancer Res 2004; 10: 3317–26.
- 68Williamson SR, Zhang S, Lopez-Beltran A, Montironi R, Wang M, Cheng L. Telomere shortening distinguishes inverted urothelial neoplasms. Histopathology 2013; 62: 595–601.
- 69Tong GX, Yee H, Chiriboga L, Hernandez O, Waisman J. Fascin-1 expression in papillary and invasive urothelial carcinomas of the urinary bladder. Hum Pathol 2005; 36: 741–6.
- 70Lechpammer M, Resnick MB, Sabo E, Yakirevich E, Greaves WO, Sciandra KT, et al. The diagnostic and prognostic utility of claudin expression in renal cell neoplasms. Mod Pathol 2008; 21: 1320–9.
- 71Stravoravdi P, Natsis K, Kirtsis P, Retalis G, Konstandinidis E, Polyzonis M. Ultrastructural study of the noninvolved urothelium of tumor-bearing patients after two years of intravesical interferon therapy. Eur Urol 1996; 29: 477–82.
- 72Szekely E, Torzsok P, Riesz P, Korompay A, Fintha A, Szekely T, et al. Expression of claudins and their prognostic significance in noninvasive urothelial neoplasms of the human urinary bladder. J Histochem Cytochem 2011; 59: 932–41.
- 73Hermann GG, Mogensen K, Carlsson S, Marcussen N, Duun S. Fluorescence-guided transurethral resection of bladder tumours reduces bladder tumour recurrence due to less residual tumour tissue in Ta/T1 patients: a randomized two-centre study. BJU Int 2011; 108: 297–303.